Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2020 Jan 15;20(5):e221–e238. doi: 10.1016/j.clml.2020.01.001

Figure 2:

Figure 2:

Clinical outcomes (all patients n=136). (a) Progression free survival for all patients (n=136), (b) PFS by MRD status post initial therapy or ASCT, (c) PFS by high versus low/standard risk myeloma patients, (d) PFS according to genetic risk and MRD status, (e) PFS according to genetic risk in MRD positive patients, (f) PFS according to genetic risk in MRD negative patients